Kathyrn Masselam Hatch, MD
Ophthalmology · Watham, MANPI 1528265824
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $67,337 of the $87,758 with a category attached, or 76.7%. 24 manufacturers reported payments, led by Glaukos Corporation at 41.4% of the total. Among ophthalmology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 150 payments — averaging $585.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$36K
- Carl Zeiss Meditec, Inc.$18K
- Avedro Inc.$9K
- Johnson & Johnson Surgical Vision, Inc.$7K
- Tarsus Pharmaceuticals, Inc.$5K
- Kala Pharmaceuticals, Inc.$3K
- plus $10K from 18 others
What the payments were for
- Consulting fees$67,33777%
- Speaking & faculty fees$10,85312%
- Travel & lodging$2,2313%
- Food & beverage$7,3018%
- Gifts$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 36 | $36,319 |
| Carl Zeiss Meditec, Inc. | 15 | $18,140 |
| Avedro Inc. | 2 | $9,001 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $6,523 |
| Tarsus Pharmaceuticals, Inc. | 8 | $5,239 |
| Kala Pharmaceuticals, Inc. | 5 | $2,906 |
| Sun Pharmaceutical Industries Inc. | 17 | $2,593 |
| Eyevance Pharmaceuticals LLC | 11 | $1,872 |
| Alcon | 12 | $1,751 |
| Sight Sciences, Inc. | 7 | $1,520 |
| Carl Zeiss Meditec USA, Inc. | 6 | $492 |
| Rxsight Inc | 5 | $485 |
| AbbVie | 3 | $137 |
| Biotissue Holdings Inc. | 1 | $135 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $118 |
| Oyster Point Pharma, Inc. | 1 | $109 |
| Harrow Eye, LLC | 1 | $106 |
| Rayner Intraocular Lenses Limited | 2 | $103 |
| Johnson & Johnson Vision Care, Inc. | 1 | $87 |
| Novartis | 2 | $57 |
| Shire North American Group Inc | 1 | $25 |
| Omeros Corporation | 1 | $18 |
| Ocular Therapeutix, Inc. | 1 | $18 |
| Beaver-visitec International, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VisuMax$14,371
- Epioxa$8,642
- VERACITY SURGICAL$6,725
- Compact Intuitiv$6,429
- IFS ADVANCED FEMTOSEC LASER$6,429
- INTRALASE FS FEMTOSEC LASER$6,429
- iStent inject W$5,700
- KXL System$5,448
- ARTEVO 800$4,650
- CALLISTO eye$4,100
- QUATERA 700$2,756
- CE-marked KXLA system$2,420
- Travoprost Intraocular Implant - iDose$2,343
- CEQUA$2,180
- Photrexa$1,940
- Flarex$1,572
- ILINK$1,500
- EYSUVIS$1,430
- IOLMaster 700$1,231
- OMNI(R) SURGICAL SYSTEM (US)$1,125
How this compares
$87,758 in reported general payments places this provider in the 95th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 39 | $43,492 |
| MieboPerfluorohexyloctane/Pf | 24 | $17,908 |
| XiidraLifitegrast | 16 | $15,271 |
| Restasis MultidoseCyclosporine | 25 | $14,377 |
| Cyclosporine | 30 | $10,913 |
| Loteprednol Etabonate | 27 | $3,925 |
| Prednisolone Acetate | 116 | $3,328 |
| Bromfenac Sodium | 12 | $2,250 |
| Fluorometholone | 16 | $1,313 |
| Brimonidine Tartrate | 17 | $784 |
| Doxycycline Monohydrate | 30 | $641 |
| ErythromycinErythromycin Base | 51 | $608 |
| MoxifloxacinMoxifloxacin Hcl | 24 | $507 |
| Timolol Maleate | 20 | $411 |
| ValacyclovirValacyclovir Hcl | 15 | $390 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Restasis Multidose | $137 | $57,86964 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $118 | $3,92527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 653 ophthalmology providers in Massachusetts.
Other ophthalmology in Watham
- Rishi SinghBoston$1.7M
- Peter ChangWaltham$992K
- Stephen AnesiWaltham$922K
- David LallySpringfield$328K
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Mark LatinaReading$279K
- Dean EliottBoston$250K
- Jeremy KievalLexington$232K
- Mina FarahaniBoston$227K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.